Efficacy and Safety of Seltorexant as Adjunctive Therapy in Patients With Major Depressive Disorder: Results From a Phase 2b, Randomized, Placebo-Controlled, Parallel-Group, Adaptive Dose-Finding Study

被引：0
|
作者：
Savitz, Adam [1 ]
Wajs, Ewa [1 ]
Zhang, Yun [1 ]
Xu, Haiyan [1 ]
Etropolski, Mila [1 ]
Saoud, Jay [1 ]
Luthringer, Remy [1 ]
Drevets, Wayne [1 ]
机构：
[1] Janssen Res & Dev LLC, Titusville, NJ USA
来源：
NEUROPSYCHOPHARMACOLOGY | 2019年 / 44卷 / SUPPL 1期
关键词：
Adjunctive Therapy; Major Depressive Disorder (MDD); Orexin; Seltorexant;
D O I：
暂无
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
M86
引用
收藏
页码：123 / 123
页数：1
相关论文
共 50 条
  • [31] A phase 2b, randomized, double-blinded, parallel-group, placebo-controlled study to evaluate the efficacy and safety of rezpegaldesleukin in adults with severe to very-severe alopecia areata
    Rosmarin, David
    Sadick, Neil
    Rodgers, Timothy G.
    Lain, Edward
    Osman, Lawrence
    Schleicher, Stephen
    Reich, Adam
    Szepietowski, Jacek C.
    Owczarczyk-Saczonek, Agnieszka
    Baran, Wojciech
    Kwiek, Bartlomiej
    Torz, Michal
    Zdybski, Jacek
    Chaudhry, Sohail
    Lee, Zachary
    Xu, Heng
    Liu, Yi
    Lewis, Brian
    Mellskog, Katie
    Elko-Simms, Lucinda M.
    Fanton, Christie
    Tagliaferri, Mary
    Zalevsky, Jonathan
    Lynde, Charles W.
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
  • [32] Efficacy and safety of oral lubiprostone in constipated patients with or without irritable bowel syndrome: a randomized, placebo-controlled and dose-finding study
    Fukudo, S.
    Hongo, M.
    Kaneko, H.
    Ueno, R.
    NEUROGASTROENTEROLOGY AND MOTILITY, 2011, 23 (06): : 544 - E205
  • [33] Efficacy, Safety, and Tolerability of Ansofaxine (LY03005) Extended-Release Tablet for Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Phase 2 Clinical Trial
    Mi, Weifeng
    Yang, Fude
    Li, Huafang
    Xu, Xiufeng
    Li, Lehua
    Tan, Qingrong
    Wang, Guoqiang
    Zhang, Kerang
    Tian, Feng
    Luo, Jiong
    Xia, Jielai
    Yuan, Kai
    Lu, Lin
    Deng, Jiahui
    Tian, Jingwei
    Zhang, Hongyan
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2022, 25 (03): : 252 - 260
  • [34] Efficacy and safety of aticaprant, a kappa receptor antagonist, adjunctive to oral SSRI/SNRI antidepressant in major depressive disorder: results of a phase 2 randomized, double-blind, placebo-controlled study
    Schmidt, Mark E.
    Kezic, Iva
    Popova, Vanina
    Melkote, Rama
    van der Ark, Peter
    Pemberton, Darrel J.
    Mareels, Guy
    Canuso, Carla M.
    Fava, Maurizio
    Drevets, Wayne C.
    NEUROPSYCHOPHARMACOLOGY, 2024, 49 (09) : 1437 - 1447
  • [35] The efficacy and safety of sulforaphane as an adjuvant in the treatment of bipolar depressive disorder Study protocol for a randomized, double-blinded, placebo-controlled, parallel-group clinical trial
    Wu, Congchong
    Chen, Xingyang
    Lai, Jianbo
    Xu, Yi
    Hu, Shaohua
    MEDICINE, 2020, 99 (26) : E20981
  • [36] One-year Efficacy and Safety Results of Secukinumab in Patients With Rheumatoid Arthritis: Phase II, Dose-finding, Double-blind, Randomized, Placebo-controlled Study
    Genovese, Mark C.
    Durez, Patrick
    Richards, Hanno B.
    Supronik, Jerzy
    Dokoupilova, Eva
    Aelion, Jacob A.
    Lee, Sang-Heon
    Codding, Christine E.
    Kellner, Herbert
    Ikawa, Takashi
    Hugot, Sophie
    Ligozio, Gregory
    Mpofu, Shephard
    JOURNAL OF RHEUMATOLOGY, 2014, 41 (03) : 414 - 421
  • [37] Efficacy of adjunctive low-dose cariprazine in major depressive disorder: a randomized, double-blind, placebo-controlled trial
    Fava, Maurizio
    Durgam, Suresh
    Earley, Willie
    Lu, Kaifeng
    Hayes, Robert
    Laszlovszky, Istvan
    Nemeth, Gyorgy
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2018, 33 (06) : 312 - 321
  • [38] Orismilast in moderate-to-severe psoriasis: Efficacy and safety from a 16-week, randomized, double-blinded, placebo-controlled, dose-finding, and phase 2b trial (IASOS)
    Warren, Richard B.
    French, Lars E.
    Blauvelt, Andrew
    Langley, Richard G.
    Egeberg, Alexander
    Mrowietz, Ulrich
    Hunter, Hamish J. A.
    Gooderham, Melinda
    Soerensen, Per
    Andres, Philippe
    Sommer, Morten O. A.
    Carlsson, Anna
    Kjoller, Kim D.
    Strober, Bruce E.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 90 (03) : 494 - 503
  • [39] Efficacy and safety of Dimdazenil in the adult insomnia patients: a phase II randomized, multicenter, double-blind, placebo-controlled, and parallel-group study
    Li, Yanpeng
    Zhang, Ruoxi
    Zhou, Yanling
    Bao, Cungang
    Lin, Zhaocun
    Chen, Chunyan
    He, Jingjing
    Jin, Zhiping
    Song, Lihua
    Zhang, Min
    Guo, Sigen
    Jiang, Yu
    Zhao, Zhongxin
    SLEEP, 2024, 47 (02)
  • [40] Efficacy of empagliflozin as adjunctive therapy to citalopram in major depressive disorder: a randomized double-blind, placebo-controlled clinical trial
    Atefeh Zandifar
    Maryam Panahi
    Rahim Badrfam
    Mostafa Qorbani
    BMC Psychiatry, 24
12345